Differential time-dependent transcriptional changes in the osteoblast lineage in cortical bone associated with sclerostin antibody treatment in ovariectomized rats.
Bone Rep
; 8: 95-103, 2018 Jun.
Article
em En
| MEDLINE
| ID: mdl-29955627
ABSTRACT
Inhibition of sclerostin with sclerostin antibody (Scl-Ab) results in stimulation of bone formation on cancellous (Cn), endocortical (Ec), and periosteal (Ps) surfaces in rodents and non-human primates. With long-term dosing of Scl-Ab, the increase in bone formation is not sustained, attenuating first on Cn surfaces and later on Ec and Ps surfaces. In Cn bone, the attenuation in bone formation (self-regulation) is associated with transcriptional changes in the osteocyte (OCy) that would limit mitogenesis and are sustained with continued dosing. The expression changes in Cn OCy occur coincident with a decrease in osteoprogenitor (OP) numbers that may directly or indirectly be a consequence of the transcriptional changes in the OCy to limit OP proliferation. To characterize the Scl-Ab-mediated changes in cortical (Ct) bone and compare these changes to Cn bone, densitometric, histomorphometric, and transcriptional analyses were performed on femur diaphyses from aged ovariectomized rats. Animals were administered 50â¯mg/kg/wk of Scl-Ab or vehicle for up to 6â¯months (183â¯days), followed by a treatment-free period (up to 126â¯days). Scl-Ab increased Ct mass and area through day 183, which declined slightly when treatment was discontinued. Ps and Ec bone formation was sustained through the dosing on both Ct surfaces, with evidence of a decline in bone formation only at day 183 on the Ec surface. This is in contrast to Cn bone, where reduced bone formation was observed after day 29. TaqMan analysis of 60 genes with functional roles in the bone using mRNA isolated from laser capture micro-dissection samples enriched for Ec osteoblasts and Ct OCy suggest a pattern of gene expression in Ct bone that differed from Cn, especially in the OCy, and that corresponded to observed differences in the timing of phenotypic changes. Notable with Scl-Ab treatment was a "transcriptional switch" in Ct OCy at day 183, coincident with the initial decline in bone formation on the endocortex. A consistent sustained increase of expression for most genes in response to Scl-Ab was observed from day 8 through day 85 at the times of maximal bone formation on both Ct surfaces; however, at day 183, this increase was reversed, with expression of these genes generally returning to control values or decreasing compared to vehicle. Genes exhibiting this pattern included Wnt inhibitors Sost and Dkk1, though both had been up-regulated until the end of dosing in Cn OCy. Changes in cell cycle genes such as Cdkn1a and Ndrg1 in Ct OCy suggested up-regulation of p53 signaling, as observed in Cn OCy; however, unlike in Cn bone, p53 signaling was not associated with decreased bone formation and was absent at day 183, when bone formation began to decline on the Ec surface. These data demonstrate involvement of similar molecular pathways in Ct and Cn bone in response to Scl-Ab but with a different temporal relationship to bone formation and suggest that the specific mechanism underlying self-regulation of Scl-Ab-induced bone formation may be different between Cn and Ct bone.
ANOVA, analysis of variance; Anabolics; BMC, bone mineral content; BMP, bone morphogenetic protein; BS, bone surface; Bone; Cn, cancellous; Ct, cortical; Ec, endocortical; Ec.Pm, endocortical perimeter; LC, lining cells; LCM, laser capture micro-dissection; MS/BS, mineralizing surface; OB, osteoblast(s); OCy, osteocyte(s); OP, osteoprogenitor(s); OPG, osteoprotegerin; OVX, ovariectomized; Osteoporosis; Ps, periosteal; Ps.Pm, periosteal perimeter; RANKL, receptor activator of nuclear factor kappa-B ligand; Scl-Ab, sclerostin antibody; Scl-AbVI, 50â¯mg/kg of a Scl-Ab; TFP, treatment-free period; TGF, transforming growth factor; TP, treatment period; Therapeutics; VEH, vehicle; Wnt signaling; pQCT, peripheral quantitative computed tomography; s.c., subcutaneous
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Tipo de estudo:
Risk_factors_studies
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article